BINDERS FOR TOXINS, MYCOTOXINS, BACTERIAL TOXINS
CIRS, CANCER-CAUSING CHEMICALS WITH RESEARCH

Binders with Research

“Binders” we define as oral substances that remain largely in the gastrointestinal tract and adsorb, sequester, or ion-exchange specific compounds.

Here are 20 with meaningful human-use data. But only a few have direct evidence for removing environmental toxicants; many others are validated binders for bile acids, potassium, phosphate, drugs, or radionuclides rather than broad “detox” agents.

20 binders used in humans

#	Binder	What it actually binds / removes	Human evidence	Relevance to environmental toxins
1	Activated charcoal	Many drugs and organic toxins in GI tract	★★★★★	High for selected acute ingestions
2	Cholestyramine	Bile acids; interrupts enterohepatic recycling	★★★★★	Direct human evidence for PCBs/PCDFs
3	Prussian blue	Cesium and thallium	★★★★★	Very high, but highly specific
4	Colesevelam	Bile acids	★★★★★	Plausible for enterohepatically recycled chemicals; little direct toxin evidence
5	Colestipol	Bile acids	★★★★★	Same limitation as colesevelam
6	Diosmectite / smectite	Adsorbs intestinal substances; mucosal barrier effects	★★★★	Human GI evidence; not proven systemic detoxifier
7	Modified citrus pectin	Metals/metal ions proposed	★★–★★★	Small human studies for Pb, Cd, As
8	Sodium alginate	Metal ions and other luminal compounds	★★	Old human lead-absorption evidence
9	Sevelamer	Phosphate, bile acids, some gut molecules	★★★★★ for phosphate	Experimental/limited for uremic toxins
10	Chitosan	Lipids/bile-associated compounds	★★★	No good evidence for systemic environmental detox
11	Sodium zirconium cyclosilicate	Potassium	★★★★★	Not a general toxin binder
12	Patiromer	Potassium	★★★★★	Not a general toxin binder
13	Sodium polystyrene sulfonate	Potassium	★★★★	Not general detox
14	Calcium acetate	Phosphate	★★★★★	Not general detox
15	Calcium carbonate	Phosphate	★★★★	Not general detox
16	Lanthanum carbonate	Phosphate	★★★★★	Not general detox
17	Ferric citrate	Phosphate	★★★★★	Not general detox
18	Sucroferric oxyhydroxide	Phosphate	★★★★★	Not general detox
19	Magnesium-containing phosphate binders	Phosphate	★★★	Not environmental detox
20	Bile-acid sequestrant class generally	Bile acids/enterohepatic molecules	★★★★★	Potential relevance for selected lipophilic compounds

1. Activated charcoal

Activated charcoal has the most extensive human toxicology literature of any oral adsorbent. It physically adsorbs many drugs and poisons and reduces their intestinal absorption. It is not effective for every toxin: metals such as lead, arsenic and iron, lithium, alcohols and several other chemicals are poorly adsorbed. Current international toxicology recommendations emphasize selected acute poisonings rather than routine chronic use.

Full references

Hoegberg LCG, Gosselin S, Buckley NA, et al. Recommendations from the Clinical Toxicology Recommendations Collaborative on the administration of activated charcoal in acute oral overdose. Clinical Toxicology. 2026;64(6):419-475. doi:10.1080/15563650.2025.2609807.

Juurlink DN, et al. Systematic review on the use of activated charcoal for gastrointestinal decontamination following acute oral overdose. Clinical Toxicology. 2021. doi:10.1080/15563650.2021.1961144.

Chyka PA, Seger D, Krenzelok EP, Vale JA. Position paper: single-dose activated charcoal. Clinical Toxicology. 2005;43(2):61-87.

2. Cholestyramine

Cholestyramine is particularly interesting for environmental medicine because it can interrupt enterohepatic recirculation.

In patients with Yusho, a mass poisoning involving PCB and polychlorinated dibenzofuran contamination, cholestyramine was specifically studied to increase fecal elimination of these compounds.

This provides considerably better human evidence than exists for most commercial “detox binders.”

Full reference

Iida T, Hirakawa H, Matsueda T, Takenaka S, Nagayama J. Therapeutic trial for promotion of fecal excretion of PCDFs and PCBs by administration of cholestyramine in Yusho patients. Fukuoka Igaku Zasshi. 1991;82(5):317-325. PMID: 1916604.

3. Prussian blue

Insoluble Prussian blue is an authentic medical decorporation agent, rather than a generalized supplement binder.

It binds:

• radioactive cesium-137
• nonradioactive cesium
• thallium

in the intestine and interrupts enterohepatic recirculation.

During the Goiânia cesium-137 accident, 46 human patients received Prussian blue, providing unusually direct clinical evidence for a toxin/radionuclide binder.

Full references

Farina R, Brandão-Mello CE, Oliveira AR. Medical aspects of 137Cs decorporation: the Goiânia radiological accident. Health Physics. 1991;60(1):63-66. PMID: 1983984.

Hoffman RS. Thallium toxicity and the role of Prussian blue in therapy. Toxicological Reviews. 2003;22(1):29-40. PMID: 14579545.

Thompson DF, Callen ED. Soluble or insoluble Prussian blue for radiocesium and thallium poisoning? Annals of Pharmacotherapy. 2004;38(9):1509-1514.

4. Colesevelam

Colesevelam is a potent, nonabsorbed bile-acid sequestrant. Randomized human trials demonstrate that it captures bile acids and increases their fecal delivery.

However, that does not demonstrate that colesevelam removes mycotoxins, PFAS, pesticides or other environmental chemicals from humans. That extrapolation requires toxin-specific evidence.

Full reference

Borup C, Vinter-Jensen L, Jørgensen SPG, et al. Efficacy and safety of colesevelam for the treatment of bile acid diarrhoea: a double-blind, randomised, placebo-controlled, phase 4 clinical trial. Lancet Gastroenterology & Hepatology. 2023;8(4):321-331. doi:10.1016/S2468-1253(22)00401-0.

Vijayvargiya P, Camilleri M, Carlson P, et al. Effects of colesevelam on bowel symptoms, biomarkers, and colonic mucosal gene expression in patients with bile acid diarrhea in a randomized trial. Clinical Gastroenterology and Hepatology. 2020. doi:10.1016/j.cgh.2020.02.027.

5. Colestipol

Colestipol is another nonabsorbed anion-exchange resin with well-demonstrated human bile-acid binding.

Full reference

Cooper EE, Michel AM. Colestipol hydrochloride, a new hypolipidemic drug: a two-year study. Southern Medical Journal. 1975;68(3):303-309. doi:10.1097/00007611-197503000-00011.

Briones ER, Steiger D, Palumbo PJ, Kottke BA. Primary hypercholesterolemia: effect of treatment on serum lipids, lipoprotein fractions, cholesterol absorption, sterol balance, and platelet aggregation. Mayo Clinic Proceedings. 1984;59(4):251-257. doi:10.1016/S0025-6196(12)61258-0.

6. Diosmectite / smectite

Diosmectite is a natural hydrated aluminum-magnesium silicate with substantial adsorptive capacity in the GI tract.

A randomized double-blind trial of 346 adults showed that diosmectite significantly shortened recovery time from acute watery diarrhea.

It has been shown in vitro to adsorb a variety of drug/toxin molecules, although charcoal remains the established toxicology adsorbent.

Full references

Khediri F, Mrad AI, Azzouz M, et al. Efficacy of diosmectite (Smecta) in the treatment of acute watery diarrhoea in adults: a multicentre, randomized, double-blind, placebo-controlled parallel group study. Gastroenterology Research and Practice. 2011;2011:783196. doi:10.1155/2011/783196.

Martínková M, et al. The capacity and effectiveness of diosmectite and charcoal in trapping compounds causing frequent intoxications in acute medicine: a comparative study. Environmental Toxicology and Pharmacology. 2017. doi:10.1016/j.etap.2017.04.011.

7. Modified citrus pectin

This is one of the few commonly promoted natural “detox” agents with actual human metal-excretion studies, although the evidence remains small and preliminary.

A pilot human study reported increased urinary excretion of:

• arsenic
• cadmium
• lead

following modified citrus pectin.

Another study in children with elevated lead reported reductions in measured lead and increased urinary excretion, but this was not a large high-quality randomized trial.

Full references

Eliaz I, Hotchkiss AT, Fishman ML, Rode D. The effect of modified citrus pectin on urinary excretion of toxic elements. Phytotherapy Research. 2006;20(10):859-864. PMID: 16835878.

Zhao ZY, Liang L, Fan X, Yu Z, Hotchkiss AT, Wilk BJ, Eliaz I. The role of modified citrus pectin as an effective chelator of lead in children hospitalized with toxic lead levels. Alternative Therapies in Health and Medicine. 2008;14(4):34-38. PMID: 18616067.

I would classify MCP as promising but not comparable to medically established chelation therapy for significant lead poisoning.

8. Sodium alginate

Alginate can bind divalent metal ions.

Importantly, there is an actual human experiment demonstrating an effect of alginate on lead absorption.

Full reference

Harrison GE, Carr TE, Sutton A, Humphreys ER, Rundo J. Effect of alginate on the absorption of lead in man. Nature. 1969;224:1115-1116. doi:10.1038/2241115b0.

Alginate also remains largely undigested through the upper GI tract and can alter intestinal sterol/fat handling.

9. Sevelamer

Sevelamer is a nonabsorbed polymer primarily designed to bind phosphate.

It also binds other gastrointestinal molecules, including bile acids, endotoxin-related material and some advanced glycation products.

However, a randomized human trial found no significant lowering of several gut-derived uremic toxins despite interesting in-vitro binding findings.

Full reference

Biruete A, Hill Gallant KM, Lindemann SR, et al. Phosphate binders and nonphosphate effects in the gastrointestinal tract. Journal of Renal Nutrition. 2020;30(1):4-10. doi:10.1053/j.jrn.2019.01.004.

Evenepoel P, et al. The effect of sevelamer on serum levels of gut-derived uremic toxins: results from in vitro experiments and a multicenter, double-blind, placebo-controlled randomized clinical trial. Toxins. 2019;11(5):279. doi:10.3390/toxins11050279.

10. Chitosan

Chitosan is a positively charged polysaccharide capable of binding lipids and some negatively charged molecules.

Human randomized trials support a modest lipid-binding/lipid-lowering effect, but I would not call it a proven heavy-metal or environmental-toxin detoxifier.

Full reference

Bokura H, Kobayashi S. Chitosan decreases total cholesterol in women: a randomized, double-blind, placebo-controlled trial. European Journal of Clinical Nutrition. 2003;57:721-725. PMID: 12771974.

Huang H, et al. Lipid-modifying effects of chitosan supplementation in humans: a pooled analysis with trial sequential analysis. Molecular Nutrition & Food Research. 2018;62(8):1700842. doi:10.1002/mnfr.201700842.

11. Patiromer

Patiromer is a nonabsorbed gastrointestinal potassium-binding polymer with strong randomized human evidence.

Full reference

Weir MR, Bakris GL, Bushinsky DA, et al.; OPAL-HK Investigators. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. New England Journal of Medicine. 2015;372(3):211-221. doi:10.1056/NEJMoa1410853.

12. Sodium zirconium cyclosilicate

A highly selective inorganic potassium binder.

A phase III trial involving 753 patients demonstrated significant potassium lowering compared with placebo.

Full reference

Packham DK, Rasmussen HS, Lavin PT, et al. Sodium zirconium cyclosilicate in hyperkalemia. New England Journal of Medicine. 2015;372(3):222-231. doi:10.1056/NEJMoa1411487.

13. Sodium polystyrene sulfonate

An older cation-exchange resin that binds potassium.

Full reference

Lepage L, Dufour AC, Doiron J, et al. Randomized clinical trial of sodium polystyrene sulfonate for the treatment of mild hyperkalemia in CKD. Clinical Journal of the American Society of Nephrology. 2015;10(12):2136-2142. PMID: 26576619.

14–18. Established phosphate binders

These are genuine gastrointestinal binders but should not be confused with environmental detoxification agents:

calcium acetate, calcium carbonate, lanthanum carbonate, ferric citrate, and sucroferric oxyhydroxide all bind dietary phosphate and are routinely used in CKD.

A useful comprehensive review covering these agents is:

Biruete A, Hill Gallant KM, Lindemann SR, et al. Phosphate binders and nonphosphate effects in the gastrointestinal tract. Journal of Renal Nutrition. 2020;30(1):4-10. doi:10.1053/j.jrn.2019.01.004.

Their strong clinical evidence is for hyperphosphatemia, not environmental toxin removal.

19. Magnesium-containing phosphate binders

Magnesium-containing preparations can bind intestinal phosphate and have been studied in dialysis patients, although their use is much less widespread than sevelamer, calcium acetate or lanthanum.

Again, this is ion binding, not broad detoxification.

20. Bile-acid sequestrants as a class

The most intriguing binder class for chronic lipophilic contaminants is probably the bile-acid sequestrants, because compounds undergoing biliary secretion and enterohepatic recycling may theoretically be trapped and carried out in stool.

The strongest direct example is cholestyramine in PCB/PCDF-exposed Yusho patients.

Colesevelam and colestipol clearly bind bile acids in humans, but direct evidence that they substantially lower human body burdens of PFAS, pesticides, mycotoxins, PCBs or dioxins should be demonstrated individually rather than assumed from their bile-binding properties.

For the environmental toxins we discussed earlier

If the real question is which binders have the best human evidence for reducing environmental toxin burden, I would shorten the list dramatically:

1. Prussian blue — cesium/thallium
2. Cholestyramine — PCB/PCDF enterohepatic elimination evidence
3. Activated charcoal — selected acute organic toxicant ingestions
4. Alginate — human evidence reducing lead absorption
5. Modified citrus pectin — preliminary human Pb/Cd/As evidence

Diosmectite, colesevelam, colestipol, chitosan and sevelamer are genuine gastrointestinal binders, but evidence that they clinically remove systemic environmental toxicants is much less established.

SCHALLER MD RESEARCH ON PULVERIZED CHLORELLA. About 1998, bioray.com ASKED ME TO RESEARCH THEIR IMMENSE SURFACE AREA IN THEIR PULVERAZATION OF CHLORELLA.

**The results were that their NDF, immensely fragmented chlorella, bound many types of metals in 60-120 minutes, and nothing metal after that. We did not look for other types of toxins in the urine.

These three below deserve inclusion, but the literature gives a very different answer for each toxin. Bentonite/calcium montmorillonite has particularly convincing human evidence for aflatoxin binding; zeolite/clinoptilolite now has controlled human evidence for reducing intestinal lead uptake; Chlorella has positive mammalian studies but also an important negative cadmium study.

Add these three to the binder master table

Binder	Laboratory binding	Mammal studies	Human studies	Best-supported target	Overall verdict
Zeolite / clinoptilolite	SUCCEEDS	SUCCEEDS for several metals in models	SUCCEEDS for reducing Pb absorption; promising treatment data	Lead; metal ion adsorption	PROMISING–GOOD, toxin-specific
Bentonite / calcium montmorillonite	STRONGLY SUCCEEDS	STRONGLY SUCCEEDS	SUCCEEDS	Aflatoxin B1	STRONG evidence for aflatoxin
Chlorella vulgaris / pyrenoidosa	SUCCEEDS for some compounds/metals	MIXED: succeeds for Pb and some Cd toxicity endpoints; fails for Cd elimination in one study	LIMITED positive evidence	Dioxins; dietary carcinogens; metals experimentally	PROMISING but not established detox therapy

1. ZEOLITE / CLINOPTILOLITE

Laboratory: SUCCEEDS

Clinoptilolite is a microporous aluminosilicate with substantial cation-exchange and adsorption capacity. Laboratory studies demonstrate binding/removal of metal ions including:

• Pb²⁺
• Cd²⁺
• Zn²⁺
• Cu²⁺
• some ammonium and other cations.

But “zeolite” is not one standardized substance. Mineral composition, particle size, purification and pre-existing metal contamination matter enormously.

Mammals: SUCCEEDS

Animal studies have reported decreased absorption or toxicity from metals including lead. The important mechanistic concept is probably intestinal sequestration, rather than systemic chelation: purified clinoptilolite remains primarily in the GI tract and can reduce uptake of ingested metal.

Humans: NOW POSITIVE

A particularly important randomized, double-blind, placebo-controlled study used the stable isotope ²⁰⁴Pb in 42 healthy adults.

Without clinoptilolite, maximum blood enrichment from the lead tracer was 0.505%, compared with 0.073% with 2 g clinoptilolite and 0.057% with two 2-g doses. Lead-tracer AUC was also markedly reduced.

Verdict: SUCCEEDS at reducing intestinal lead uptake in humans.

That is considerably stronger evidence than simply demonstrating metal adsorption in a test tube.

New clinical lead-poisoning evidence

An additional double-blind randomized clinical trial involved 80 adults with mild-to-moderate lead poisoning. After two weeks, the zeolite group had lower serum lead concentrations than controls (25.22 ± 13.26 vs 37.68 ± 15.34; P < .001).

This is encouraging, although it should be replicated independently before clinoptilolite is considered equivalent to established lead-poisoning therapies.

Full references

Zhakov YI, et al. [Clinoptilolite/zeolite studies referenced in subsequent clinical literature]. The modern human clinical literature is summarized in the following controlled study:

Kraljević Pavelić S, Saftić Martinović L, Simović Medica J, et al. Clinical evaluation of a defined zeolite-clinoptilolite supplementation effect on the selected blood parameters of patients. Frontiers in Medicine. 2022;9:851782. doi:10.3389/fmed.2022.851782.

Concomitant oral intake of purified clinoptilolite tuff (G-PUR) reduces enteral lead uptake in healthy humans. Randomized, placebo-controlled, double-blind stable-isotope study.

Oral Zeolite Therapy for Management of Mild to Moderate Lead Poisoning: A Randomized Clinical Trial. Randomized double-blind trial, 80 patients.

Bottom line: ZEOLITE = SUCCESS for reducing GI lead absorption; promising but incomplete evidence for lowering established body burdens.

2. BENTONITE / CALCIUM MONTMORILLONITE

This one moves substantially higher on the binder list when the toxin of interest is aflatoxin.

Laboratory: STRONG SUCCESS

Calcium montmorillonite binds aflatoxin B1 (AFB1) very strongly.

Binding has been demonstrated under acidic and near-neutral conditions relevant to the gastrointestinal tract.

A 2020 study characterized binding thermodynamics and demonstrated very high-capacity aflatoxin adsorption by selected bentonite clay.

Full reference

Wang M, Hearon SE, Phillips TD. A high capacity bentonite clay for the sorption of aflatoxins. Food Additives & Contaminants: Part A. 2020;37(2):332-341. doi:10.1080/19440049.2019.1662493.

Mammals: STRONG SUCCESS

This is backed by extensive animal literature. Calcium montmorillonite/NovaSil:

• binds AFB1 in the GI tract;
• reduces its bioavailability;
• decreases aflatoxin biomarkers;
• reduces hepatic toxicity;
• reduces morbidity/mortality in animal aflatoxicosis models.

The extensive animal and human literature is reviewed here.

Humans: SUCCESS

This is where bentonite becomes especially interesting.

177-person randomized trial

A three-month double-blind, placebo-controlled clinical trial in Ghana randomized 177 participants to:

• 3.0 g/day NovaSil,
• 1.5 g/day NovaSil,
• placebo.

The treatment was well tolerated.

More importantly, serum AFB1-albumin adducts were significantly reduced at three months in both clay groups compared with placebo.

Full references

Afriyie-Gyawu E, Ankrah NA, Huebner HJ, et al. NovaSil clay intervention in Ghanaians at high risk for aflatoxicosis. I. Study design and clinical outcomes. Food Additives and Contaminants. 2008;25(1):76-87.

Wang P, Afriyie-Gyawu E, Tang Y, et al. NovaSil clay intervention in Ghanaians at high risk for aflatoxicosis: II. Reduction in biomarkers of aflatoxin exposure in blood and urine. Food Additives and Contaminants Part A. 2008;25(5):622-634.

Human crossover study: 55% reduction

A crossover trial found that refined calcium montmorillonite reduced urinary AFM1 biomarkers by approximately 55% compared with placebo.

Children: also positive

In a randomized intervention involving 200 Ghanaian children aged 2–9, calcium montmorillonite treatment was associated with approximately a 60% reduction in urinary AFM1, whereas AFM1 increased in the placebo group.

Another pediatric study found a significant reduction in urinary AFM1 with the higher clay dose without attributable adverse events.

Bottom line: BENTONITE/CALCIUM MONTMORILLONITE = STRONG SUCCESS for reducing gastrointestinal aflatoxin bioavailability.

That does not establish bentonite as a universal binder for ochratoxin, trichothecenes, metals, PFAS, pesticides, etc. Each toxin needs separate evidence.

3. CHLORELLA-Schaller 1999 research found that the bioray.com NDF, which is immensely pulverized, removed metals in under 2 hours.

Chlorella is scientifically interesting because it produces both positive and negative experiments. That makes it a good example of why we should not simply label a compound a “detoxifier.”

Laboratory: POSITIVE for some compounds

Chlorella biomass and cell-wall material can adsorb metal ions under laboratory conditions.

However, in-vitro adsorption does not establish removal of metals already stored in mammalian tissues.

Mammals — LEAD: SUCCESS

A particularly relevant 2025 experiment used 40 Wistar rats exposed to lead.

Chlorella vulgaris supplementation:

• decreased lead accumulation in blood;
• decreased lead in liver;
• decreased lead in kidney;
• improved oxidative-stress parameters;
• restored memory performance toward control values.

Interestingly, brain lead itself did not show the same clear reduction, despite functional improvement.

Full reference

Diaz JP, Pena E, El Alam S, Matte C, Cortés I, Figueroa L, Siques P, Brito J. Chlorella vulgaris supplementation attenuates lead accumulation, oxidative stress, and memory impairment in rats. Toxics. 2025;13(4):313. doi:10.3390/toxics13040313.

Verdict for Pb in rats: SUCCESS.

4. CHLORELLA + CADMIUM — POSITIVE STUDY

Another rat experiment found that C. vulgaris reduced hepatic cadmium concentrations and attenuated cadmium-induced liver pathology.

Full reference

Shim JY, Shin HS, Han JG, Park HS, Lim BL, Chung KW, Om AS. Protective effects of Chlorella vulgaris on liver toxicity in cadmium-administered rats. Journal of Medicinal Food. 2008;11(3):479-485. doi:10.1089/jmf.2007.0075.

A more recent rat experiment also found substantial protection against cadmium-induced hepatic and renal injury involving Nrf2 and NF-κB pathways.

Farag MR, Alagawany M, Mahdy EAA, et al. Benefits of Chlorella vulgaris against cadmium chloride-induced hepatic and renal toxicities via restoring the cellular redox homeostasis and modulating Nrf2 and NF-κB pathways in male rats. Biomedicines. 2023;11(9):2414. doi:10.3390/biomedicines11092414.

So there is genuine mammalian evidence of protection against cadmium toxicity.

5. CHLORELLA + CADMIUM — IMPORTANT FAILURE

But another well-designed rat experiment produced a different answer.

After cadmium exposure had stopped, rats received diets containing 0%, 5%, or 10% Chlorella.

Chlorella did not significantly increase urinary cadmium excretion and did not significantly improve the relevant cadmium detoxification endpoints.

Full reference

Kim YJ, Kwon S, Kim MK. Effect of Chlorella vulgaris intake on cadmium detoxification in rats fed cadmium. Nutrition Research and Practice. 2009;3(2):89-94. doi:10.4162/nrp.2009.3.2.89. PMID: 20016707.

Verdict: FAILURE for accelerating established cadmium elimination in this model.

This distinction is important:

Reducing absorption/tissue accumulation during ongoing exposure ≠ removing previously accumulated metal after exposure stops.

6. CHLORELLA + DIOXINS — HUMAN SIGNAL

There is also an intriguing human study.

Thirty-five pregnant Japanese women were studied; 18 took Chlorella pyrenoidosa during pregnancy.

Dioxin toxic equivalents were significantly lower in breast milk from Chlorella users than controls (P=.003).

Full reference

Nakano S, Takekoshi H, Nakano M. Chlorella (Chlorella pyrenoidosa) supplementation decreases dioxin and increases immunoglobulin A concentrations in breast milk. Journal of Medicinal Food. 2007;10(1):134-142. doi:10.1089/jmf.2006.023. PMID: 17472477.

However, this was not a large randomized detoxification trial, so I would classify it as a positive human signal rather than proof of therapeutic dioxin removal.

7. CHLORELLA + DIETARY CARCINOGENS — HUMAN RCT

There is another small but randomized human experiment involving dietary heterocyclic amines.

Six women participated in a randomized, double-blind, placebo-controlled crossover study of Chlorella supplementation for two weeks examining detoxification of carcinogenic heterocyclic amines.

Full reference

Lee SH, et al. Detoxification of chlorella supplement on heterocyclic amines in Korean young adults. Environmental Toxicology and Pharmacology. 2015;39(1). doi:10.1016/j.etap.2014.11.015. PMID: 25590673.

The sample size of six makes this hypothesis-generating rather than definitive.

Revised ranking of these three

For specific toxin-binding evidence, I would rank them:

1. Calcium montmorillonite/bentonite → AFLATOXIN: ★★★★★

Laboratory SUCCESS
Animal SUCCESS
Human SUCCESS
Multiple controlled human studies.

2. Clinoptilolite/zeolite → LEAD: ★★★★

Laboratory SUCCESS
Animal SUCCESS
Human prevention of GI absorption SUCCESS
Human lead-treatment trial PROMISING SUCCESS
Evidence for other systemic toxins remains insufficient.

3. Chlorella → selected metals/dioxins: ★★★

Laboratory SUCCESS for selected compounds
Lead animal model SUCCESS
Cadmium animal models MIXED
Cadmium elimination after exposure FAILURE in one study
Human dioxin study POSITIVE SIGNAL
Human evidence for actual systemic heavy-metal detoxification INSUFFICIENT.

***The most important lesson from these studies is that “binder” should always be followed by “binder of what?”

Calcium montmorillonite has surprisingly good human evidence for aflatoxin, but that does not prove it binds PFAS or lead clinically. Clinoptilolite has convincing human evidence for reducing enteral lead uptake, but that does not prove systemic mercury removal. Chlorella can reduce tissue accumulation/toxicity in some animal models while failing to accelerate elimination of an already accumulated metal in another model.

I HAVE NOT SEEN TYPICAL URINE AND BLOOD MYCOTOXIN TESTS WORK WHEN THEY ARE BLINDED TO SAMPLES FROM IDENTICAL CUP OR TUBE.